185.62
price up icon1.38%   2.53
after-market Dopo l'orario di chiusura: 185.09 -0.53 -0.29%
loading
Precedente Chiudi:
$183.09
Aprire:
$183.46
Volume 24 ore:
4.92M
Relative Volume:
0.64
Capitalizzazione di mercato:
$327.88B
Reddito:
$57.37B
Utile/perdita netta:
$4.20B
Rapporto P/E:
78.99
EPS:
2.35
Flusso di cassa netto:
$15.39B
1 W Prestazione:
+1.69%
1M Prestazione:
-4.08%
6M Prestazione:
+1.47%
1 anno Prestazione:
+19.92%
Intervallo 1D:
Value
$182.69
$186.75
Intervallo di 1 settimana:
Value
$181.72
$186.75
Portata 52W:
Value
$153.58
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Nome
Abbvie Inc
Name
Telefono
(847) 932-7900
Name
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Dipendente
55,000
Name
Cinguettio
@abbvie
Name
Prossima data di guadagno
2025-04-25
Name
Ultimi documenti SEC
Name
ABBV's Discussions on Twitter

Confronta ABBV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.62 322.44B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
722.57 642.06B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.58 367.19B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
112.58 222.20B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.46 302.90B 43.59B 15.04B 10.74B 3.3766

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-14 Downgrade Citigroup Buy → Neutral
2025-04-22 Iniziato Cantor Fitzgerald Overweight
2024-12-10 Ripresa BofA Securities Neutral
2024-12-05 Downgrade Daiwa Securities Outperform → Neutral
2024-11-22 Aggiornamento Leerink Partners Market Perform → Outperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-04 Aggiornamento Argus Hold → Buy
2024-10-17 Iniziato Bernstein Mkt Perform
2024-06-05 Aggiornamento HSBC Securities Hold → Buy
2024-05-17 Iniziato Cantor Fitzgerald Overweight
2024-01-29 Aggiornamento William Blair Mkt Perform → Outperform
2023-12-18 Downgrade HSBC Securities Buy → Hold
2023-12-11 Aggiornamento Goldman Neutral → Buy
2023-11-09 Iniziato Deutsche Bank Hold
2023-10-30 Aggiornamento Barclays Equal Weight → Overweight
2023-10-20 Ripresa UBS Neutral
2023-09-29 Iniziato Raymond James Outperform
2023-07-25 Iniziato William Blair Mkt Perform
2023-07-14 Iniziato HSBC Securities Buy
2023-04-05 Downgrade Argus Buy → Hold
2023-03-01 Iniziato Guggenheim Buy
2023-02-22 Downgrade Wolfe Research Outperform → Peer Perform
2023-02-10 Aggiornamento SVB Securities Underperform → Market Perform
2022-11-18 Iniziato Credit Suisse Outperform
2022-11-08 Downgrade Societe Generale Buy → Hold
2022-08-01 Downgrade Atlantic Equities Overweight → Neutral
2022-05-23 Iniziato SVB Leerink Underperform
2022-05-06 Downgrade Daiwa Securities Outperform → Neutral
2022-04-06 Ripresa Morgan Stanley Overweight
2022-02-28 Downgrade UBS Buy → Neutral
2022-02-03 Reiterato BMO Capital Markets Outperform
2022-02-03 Reiterato Barclays Equal Weight
2022-02-03 Reiterato BofA Securities Neutral
2022-02-03 Reiterato Goldman Neutral
2022-01-13 Iniziato Redburn Buy
2022-01-12 Reiterato BMO Capital Markets Outperform
2021-12-09 Ripresa Wells Fargo Overweight
2021-11-23 Aggiornamento Societe Generale Hold → Buy
2021-07-27 Ripresa Truist Buy
2021-04-07 Ripresa RBC Capital Mkts Outperform
2020-11-10 Ripresa Bernstein Outperform
2020-09-29 Iniziato Berenberg Hold
2020-06-23 Aggiornamento Atlantic Equities Neutral → Overweight
2020-06-09 Aggiornamento Wolfe Research Peer Perform → Outperform
2020-06-02 Aggiornamento Argus Hold → Buy
2020-05-18 Ripresa BofA/Merrill Neutral
2020-05-12 Aggiornamento JP Morgan Neutral → Overweight
2020-05-11 Ripresa Morgan Stanley Overweight
2020-04-20 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-03-23 Downgrade Societe Generale Buy → Hold
2020-02-27 Iniziato Barclays Equal Weight
2020-02-06 Iniziato Mizuho Buy
2020-01-07 Iniziato RBC Capital Mkts Sector Perform
2019-12-26 Reiterato Cowen Outperform
2019-09-26 Aggiornamento Citigroup Neutral → Buy
2019-08-20 Aggiornamento Piper Jaffray Neutral → Overweight
2019-06-27 Aggiornamento Wolfe Research Underperform → Peer Perform
2019-06-26 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-05-28 Iniziato Goldman Neutral
2019-04-29 Aggiornamento BMO Capital Markets Underperform → Market Perform
Mostra tutto

Abbvie Inc Borsa (ABBV) Ultime notizie

pulisher
May 29, 2025

Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical - MSN

May 29, 2025
pulisher
May 29, 2025

Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc.(ABBV) - TradingView

May 29, 2025
pulisher
May 29, 2025

AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip? - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

AbbVie: Fairly Valued, But Lacking A Spark - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Cancer Therapeutics Market Is Booming So Rapidly 2025-2032 - openPR.com

May 29, 2025
pulisher
May 29, 2025

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat - Yahoo Finance

May 29, 2025
pulisher
May 28, 2025

Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.

May 28, 2025
pulisher
May 28, 2025

AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Bearish Sentiment and Increased Put Activity for AbbVie (ABBV) | - GuruFocus

May 28, 2025
pulisher
May 28, 2025

AbbVie put volume heavy and directionally bearish - TipRanks

May 28, 2025
pulisher
May 28, 2025

Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies - BioSpace

May 28, 2025
pulisher
May 28, 2025

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - sharewise

May 28, 2025
pulisher
May 28, 2025

Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

AbbVie’s Allergan cuts over 200 staff after botched marketing campaign - PharmaLive

May 28, 2025
pulisher
May 27, 2025

AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit - MSN

May 27, 2025
pulisher
May 27, 2025

AbbVie To Present Cancer Trial Data At Upcoming ASCO Event - Benzinga

May 27, 2025
pulisher
May 27, 2025

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio - Investing News Network

May 27, 2025
pulisher
May 27, 2025

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio | ABBV Stock News - GuruFocus

May 27, 2025
pulisher
May 26, 2025

Tissue Engineering Market Generated Opportunities, Future - openPR.com

May 26, 2025
pulisher
May 26, 2025

Prurigo Nodularis Market - GlobeNewswire Inc.

May 26, 2025
pulisher
May 26, 2025

AbbVie’s SWOT analysis: biopharma giant faces pipeline challenges amid stock growth - Investing.com

May 26, 2025
pulisher
May 26, 2025

Precision immunology Market Growth in Future Scope 2025-2032 | - openPR.com

May 26, 2025
pulisher
May 26, 2025

Immunomodulatory Drugs Market in 2025 Detailed Study Analysis | - openPR.com

May 26, 2025
pulisher
May 26, 2025

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie - insights.citeline.com

May 26, 2025
pulisher
May 25, 2025

CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.

May 25, 2025
pulisher
May 24, 2025

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer - MSN

May 24, 2025
pulisher
May 23, 2025

Key Drivers Behind AbbVie’s (ABBV) Performance - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineABBV - marketscreener.com

May 23, 2025
pulisher
May 22, 2025

AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient - Investing News Network

May 22, 2025
pulisher
May 22, 2025

AbbVie Secures Legal Victory Over Allergan Share Dispute - USA Herald

May 22, 2025
pulisher
May 22, 2025

Interleukin Inhibitors Market Detailed In New Research Report - openPR.com

May 22, 2025
pulisher
May 22, 2025

AbbVie (ABBV) has a Stable and Highly Profitable Business Model - Insider Monkey

May 22, 2025
pulisher
May 22, 2025

Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change - Pharma Voice

May 22, 2025
pulisher
May 22, 2025

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com

May 22, 2025
pulisher
May 21, 2025

AbbVie Gets Victory In Allergan Shareholder Suit Upheld - Law360

May 21, 2025
pulisher
May 21, 2025

Court upholds dismissal of AbbVie-Allergan merger suit - Crain's Chicago Business

May 21, 2025
pulisher
May 21, 2025

AbbVie, Allergan Merger Suit Dismissal Upheld By Illinois Court - Bloomberg Law News

May 21, 2025
pulisher
May 21, 2025

Cancer Cachexia Market Detailed in New Research Report By 2032 | AbbVie Inc., Actimed Therapeutics - openPR.com

May 21, 2025
pulisher
May 21, 2025

Rheumatoid Arthritis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH - The Globe and Mail

May 21, 2025
pulisher
May 21, 2025

Plastic Surgery Market Fly Massive Growth in Years to Come: AbbVie, Johnson & Johnson Services, Sientra - openPR.com

May 21, 2025
pulisher
May 20, 2025

AbbVie Hits Last Generic-Orilissa Holdout With New Patent Suit - Bloomberg Law News

May 20, 2025
pulisher
May 20, 2025

AbbVie (ABBV) Soared on Favorable Tailwinds - MSN

May 20, 2025
pulisher
May 20, 2025

Ameriprise Financial Initiates AbbVie at Buy - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class ActionABBV - Morningstar

May 20, 2025
pulisher
May 20, 2025

Former AbbVie, Takeda omnichannel lead Dan Gandor joins Eversana Intouch - Medical Marketing and Media

May 20, 2025
pulisher
May 19, 2025

Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class ActionABBV - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie - Yahoo Finance

May 19, 2025

Abbvie Inc Azioni (ABBV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general JNJ
$153.58
price up icon 0.75%
drug_manufacturers_general NVS
$112.58
price up icon 0.63%
drug_manufacturers_general NVO
$69.46
price up icon 1.25%
drug_manufacturers_general MRK
$76.40
price up icon 0.30%
drug_manufacturers_general GSK
$40.00
price up icon 2.09%
Capitalizzazione:     |  Volume (24 ore):